Based on the dismal survival outcome of RAMhigh patients and the well-known clinical activity of ALK inhibitors in NSCLC with ALK and/or ROS1 rearrangement, an investigator-initiated phase II trial is ongoing. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.